Sana Biotechnology reports 2025 financial results and pipeline progress
Sana Biotechnology reported FY2025 results with revenue of $138 million, R&D expenses of $666 million, G&A of $203 million, and approximately $1.6 billion in cash and marketable securities. The company described progress across engineered cell and gene therapy platforms—ex vivo haematopoietic stem cell engineering and in vivo targeted delivery—with haemoglobinopathy and oncology candidates in IND‑enabling and early clinical stages, manufacturing scale‑up, and planned additional trials in 2026.
Why it matters$1.6 billion cash on hand supports operations into 2027; investors can time financing and partnership decisions accordingly.
Entities Mentioned
Sana Biotechnology, Inc